Eli Lilly shares first human trial results for LOXO-435, a selective FGFR3 inhibitor for bladder cancer, showing 41% response ...

The Trump administration’s effort to remake the federal workforce swept through US healthcare agencies on Friday, with wide ...

Johnson & Johnson is set to push for confirmation of a bankruptcy plan next week that would settle a vast majority of cases ...

Major drugmakers are planning to meet with President Donald Trump next week at the White House as part of the industry’s ...

Kojin Therapeutics, a startup attempting to develop new treatments using programmed cell death, left last month’s JP Morgan ...

Renee Wegrzyn has been let go as the head of a federal agency that pursues ambitious ideas to accelerate biomedical ...

Corbus' CRB-701 shows 23% response rate in early cancer trial, but shares fall after some patients with prior Padcev ...

West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

Bambusa Therapeutics raises $90M Series A for bispecific antibodies, led by RA Capital. Founded by BioNTech veterans, plans ...

Welcome back to Endpoints Weekly. Grab a cup of Saturday morning coffee and let’s dive straight into the news — it was a busy week!

GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.

David Schenkein will step down from Agios Phar­ma­ceu­ti­cals ’ board of di­rec­tors at the end of the month “to de­vote more ...